{"schema_version":"1.0","type":"article","title":"Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find","url":"https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.md","lang":"en","date":"2026-07-02","publish_at":"2026-07-02T10:30:00+08:00","updated_at":"2026-07-02","category":"商業分析系列","topic":"商業分析系列","tags":["synthetic lethality","PARP","PRMT5","MTAP","RAS","oncology","biomarkers","Taiwan biotech","drug development"],"summary":"PARP inhibitors turned synthetic lethality into a commercial reality. Two decades later, the industry is still asking why the next PARP-like blockbuster has been so difficult to reproduce.","key_points":[],"facts":[],"sections":["01 | Why Synthetic Lethality Is So Attractive: It Targets the Cancer Cell’s Second Survival Route","02 | Why PARP Is Hard to Copy: Most Synthetic-Lethal Relationships Are Not That Simple","03 | The First Turning Point: Synthetic Lethality May Be More Valuable as Combination Therapy Than as a Standalone Drug","04 | The Second Turning Point: PROTAC and Molecular Glue Technologies Are Opening Targets That Were Previously Hard to Drug","05 | The Third Turning Point: Biomarkers Must Become More Precise, or Clinical Benefit Will Be Diluted","06 | How Taiwan Should Look at This Field: The Key Is Not Building the Next PARP, but Diagnostics and Patient Stratification","Conclusion | Synthetic Lethality Has Not Failed. It Is Moving From Single-Agent Myth to Precision Combinations","References"],"references":[{"title":"[0] Company websites and public disclosures.","source":"","date":"","url":""},{"title":"[1] Coherent Market Insights PARP inhibitor market data.","source":"","date":"","url":""},{"title":"[2] OncoDaily review on synthetic lethality in oncology.","source":"","date":"","url":""},{"title":"[3] Repare Therapeutics public disclosure on camonsertib rights.","source":"","date":"","url":""},{"title":"[4] Fierce Biotech report on GSK and IDEAYA.","source":"","date":"","url":""},{"title":"[5] Debiopharm disclosure on lunresertib and zedoresertib.","source":"","date":"","url":""}],"images":[{"alt":"Synthetic lethality targets the second survival route of cancer cells","url":"https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp-en/figure-01.png"},{"alt":"The next PARP is difficult because biology, druggability, and patient selection rarely align at once","url":"https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp-en/figure-02.png"},{"alt":"Combination therapy may turn synthetic lethality into an amplifier of stronger oncology backbones","url":"https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp-en/figure-03.png"},{"alt":"Protein degradation technologies can unlock targets that conventional inhibitors struggle to reach","url":"https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-02）。Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find。https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-07-02-synthetic-lethality-next-parp.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}